ArticleThe South African journal of communication disorders = Die Suid-Afrikaanse tydskrif vir Kommunikasieafwykings2026
Genetic susceptibility to aminoglycoside cochleotoxicity in South African multidrug-resistant and rifampicin-resistant tuberculosis patients.
Article in The South African journal of communication disorders = Die Suid-Afrikaanse tydskrif vir Kommunikasieafwykings, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundSouth Africa has a high burden of multidrug-resistant tuberculosis (MDR-TB) and rifampicin-resistant tuberculosis (RR-TB). At the time of this study, kanamycin formed part of the South African MDR/RR-TB treatment regimen. Although treatment has shifted towards shorter all-oral regimens, aminoglycoside-related ototoxicity remains clinically relevant.
objectivesThis study investigated the association between two mitochondrial variants, m.15312TC (I189T in MT-CYB [mitochondrially encoded cytochrome b]) and m.10114TC (I19T in MT-ND3 [mitochondrially encoded NADH]), and susceptibility to cochleotoxicity in South African patients receiving kanamycin-based MDR/RR-TB treatment.
methodA prospective cohort study was conducted in Cape Town, South Africa. Hearing thresholds from 0.25 kHz to 16 kHz were monitored at baseline and at 4 weeks, 8 weeks and 12 weeks after treatment initiation. Cochleotoxicity was defined using the American Speech-Language-Hearing Association's significant threshold shift criteria. Mitochondrial variants were identified using polymerase chain reaction and Sanger sequencing. Fisher's exact tests were used to explore associations between variants and cochleotoxicity.
resultsHearing data were analysed for 102 participants. Cochleotoxicity developed in 84 participants (82.4%). The m.15312TC variant was detected in three of 78 successfully sequenced participants, and m.10114TC in four of 80. All variant carriers had cochleotoxicity. Statistically significant associations were not demonstrated for m.15312TC (p = 1.000) or m.10114TC (p = 1.000).
conclusionThe variants were observed only among participants who developed cochleotoxicity, but no statistically significant associations were observed. The findings are exploratory and require validation before clinical screening.Contribution: This study supports future genetic-susceptibility research in African aminoglycoside-exposed populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.